MBX Biosciences Inc’s filing revealed that its Former Director CORNELIUS JAMES M acquired Company’s shares for reported $1.1 million on Jan 12 ’26. In the deal valued at $35.74 per share,30,864 shares were bought.
Then, Hawryluk P. Kent bought 20,000 shares, generating $272,790 in total proceeds. Upon buying the shares at $13.64, the President & CEO now owns 468,277 shares.
Before that, Hoerter Steven L. bought 20,000 shares. MBX Biosciences Inc shares valued at $264,984 were divested by the Director at a price of $13.25 per share. As a result of the transaction, Hoerter Steven L. now holds 20,000 shares, worth roughly $0.73 million.
Goldman initiated its MBX Biosciences Inc [MBX] rating to a Sell in a research note published on December 04, 2025; the price target was $18. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early November with a ‘”a Buy”‘ rating. Truist began covering MBX with “Buy” recommendation on October 15, 2025.
Price Performance Review of MBX
On Monday, MBX Biosciences Inc [NASDAQ:MBX] saw its stock jump 15.19% to $36.47. Over the last five days, the stock has gained 24.43%. MBX Biosciences Inc shares have risen nearly 151.34% since the year began. Nevertheless, the stocks have risen 15.63% over the past one year.
How much short interest is there in MBX Biosciences Inc?
A steep rise in short interest was recorded in MBX Biosciences Inc stocks on 2025-12-31, dropping by -0.26 million shares to a total of 3.84 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 4.1 million shares. There was a decline of -6.71%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 05, 2025 when Mizuho began covering the stock and recommended ‘”an Outperform”‘ rating along with a $38 price target.
